Clinical trials: Primary
Epilepsy
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
Evaluating efficacy \& safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy…
- Trial name
- VALOR (NCT02408523)
- Testing
- Lacosamide Tablet, Lasosamide Oral Solution
- Where
- 115 sites in United States, Australia and 20 more
- Volunteers
- 242 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Healthy
Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial
The objectives of this study were to analyze the immunogenicity and reactogenicity of DTP/HB/Hib (Bio Farma) combination vaccine.
- Trial name
- NCT01986335
- Testing
- DTP/HB/Hib Vaccine
- Where
- 6 sites in Indonesia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
This study is researching a Regeneron drug called linvoseltamab ("study drug") alone compared to standard of care (SoC) combination to see if it can help treat participants who are newly diagnosed and previously untreated for…
- Trial name
- LINKER-AL1 (NCT07901725)
- Testing
- Linvoseltamab, Daratumumab, Bortezomib
- Volunteers
- 382 people
- Sponsor
- Regeneron Pharmaceuticals
Migraine
Observational Study to Assess Migraine Prediction Tool
This is a prospective, observational study. The participant will be required to approve his/her participation in the study by completing the electronic consent form.
- Trial name
- NCT05523310
- Testing
- Daily questionnaire
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Theranica
Ovarian Neoplasms
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive…
- Trial name
- NCT01329549
- Testing
- BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- Where
- 3 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Ovarian Cancer, Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer
- Trial name
- NCT06366490
- Testing
- Innocell Autologous Cellular Immunotherapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- PhotonPharma, Inc.
Open Angle Glaucoma, Primary Open Angle Glaucoma
Safety and Effectiveness of the Hydrus Microstent
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in pseudophakic patients with open-angle glaucoma for whom IOP is not sufficiently controlled on…
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
- Trial name
- FRONTIER (NCT05198297)
- Testing
- Hydrus Microstent, Ophthalmic surgery
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alcon Research
Substance Use
Online System for Primary Care to Prevent and Address Teen Substance Use
This Quality Improvement (QI) project for physician education will build on an existing platform, CHADIS (Comprehensive Health and Decision Information System; www.CHADIS.com).
- Trial name
- Substance (NCT04689997)
- Testing
- cSBI
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Total Child Health, Inc.
Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Cenobamate Open-Label Extension Study for YKP3089C025
52 Week Open-Label Safety Study of Cenobamate for Subjects who Complete YKP3089C025 (core study)
- Trial name
- NCT03961568
- Testing
- Cenobamate
- Where
- 45 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- SK Life Science, Inc.
Myelofibrosis
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with hepatic impairment after a single dose, and to evaluate the…
- Trial name
- NCT07480824
- Testing
- TQ05105
- Where
- 2 sites in China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endometrial Carcinoma, Ovarian Carcinoma
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
This trial is a Phase 1b/2a/3 trial designed to evaluate the safety and efficacy of adding oral AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to standard platinum-based chemotherapy…
- Conditions
- Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- AL3818 (NCT02584478)
- Testing
- AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 41 sites in United States, China and 4 more
- Volunteers
- 294 people
- Sponsor
- Advenchen Laboratories, LLC
Primary Open Angle Glaucoma, Pigmentary Glaucoma
Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study
The study objective is to demonstrate the safety of Minimally Invasive Micro Sclerostomy (MIMS) device for lowering elevated IOP in patients diagnosed with glaucoma.
- Conditions
- Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
- Trial name
- NCT02355990
- Testing
- Minimally Invasive Micro Sclerostomy
- Where
- Israel
- Volunteers
- 96 people
- Sponsor
- Sanoculis Ltd
Hereditary Angioedema
A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children
The main aims of this study are to learn how lanadelumab moves through a child's body and if the children have any medical problems from lanadelumab.
- Trial name
- SPRING (NCT04070326)
- Testing
- Lanadelumab
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 21 people
- Sponsor
- Shire
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- NCT07340138
- Testing
- Pelabresib, Ruxolitinib
- Where
- 3 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Pyoderma
Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)
This open-label, randomized, parallel-group clinical study is designed to compare the efficacy and safety of the topical antibiotic, sisomicin cream, with that of another topical antibiotic cream, nadifloxacin cream, in the…
- Trial name
- NCT00202891
- Testing
- sisomicin
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Type 16/18 Infection, Cervical Intraepithelial Neoplasia
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
The study will be extended for subjects who received all three doses of vaccine in Finland, Denmark and Estonia to determine long-term safety and immunogenicity of the HPV-16/18 vaccine.
- Trial name
- NCT00337818
- Testing
- Cervarix™
- Where
- Estonia
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study
This extension study is conducted to assess the efficacy of the GSK 580299 vaccine against cervical intraepithelial neoplasia (CIN) lesions, cervical cancer and cytological abnormalities associated with human papillomavirus…
- Trial name
- NCT00929526
- Testing
- Liquid-based cytology (LBC) sampling, Blood sampling
- Where
- 13 sites in Japan
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Migraine Headaches
Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
This is a Phase 1/ Phase 2, 12-week, multi-center, randomized, double-blind, cross-over, placebo-controlled study to evaluate the efficacy and safety of ELS-M11 compared to placebo in 50 male and female subjects, aged 18 to 65…
- Trial name
- NCT02057315
- Testing
- ELS-M11
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Achelios Therapeutics
Primary Membranous Nephropathy
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy
- Trial name
- NCT06470191
- Testing
- B007, Cyclosporin Capsules
- Where
- 21 sites in China
- Volunteers
- 216 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Primary Haemophagocytic Lymphohistiocytosis
Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis
The purpose of this study is to assess the safety, tolerability and efficacy of a new drug aimed at controlling disease activity in patients diagnosed with primary haemophagocytic lymphohistiocytosis.
- Trial name
- NCT01818492
- Testing
- NI-0501
- Where
- 20 sites in United States, Germany and 4 more
- Volunteers
- 45 people
- Sponsor
- Swedish Orphan Biovitrum